ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

SURVEY: Cognitive Impairment II

Top 3 Nutrients to Detox the Liver and Soothe Digestion

Natural Bladder Control, Go Less and Live More

Study bodes well for low-carb eaters

Top Vitamin and Mineral Deficiencies — Are You at Risk?

Omega Fix for Obesity: How the Right Fats Fight Fat

Potential of Quercetin in the Treatment of Melanoma

How Pomegranate May Protect Against Cancer

Vital Molecule Increases Cellular Energy and Improves Cognitive Function

Trimming the spare tire: Canola oil may cut belly fat

 
Print Page
Email Article

Drug Tested for HIV Prevention in Baltimore

  [ 128 votes ]   [ Discuss This Article ]
www.ProHealth.com • February 24, 2003


As effective vaccines against HIV remain elusive, Johns Hopkins researchers have completed the first tests to see if a drug already used to treat HIV infection might one day be used to prevent sexual and blood-borne transmission of the virus that causes AIDS.

Reported in the March 7 issue of the journal AIDS (available online now), the 12-week study of nevirapine in Baltimore is believed to be the first in the United States to evaluate a pre-exposure, drug-based prevention strategy for adults at high risk, say the researchers. Previous strategies have focused on behavioral changes such as condom use and clean needles.

"This is a new concept for prevention of HIV infection," says J. Brooks Jackson, M.D., M.B.A., director of pathology and leader of the study. "A combination of drugs is used to treat HIV infection, but we want to see if long-term, low doses of one of these drugs can prevent new HIV infections in people at high risk. HIV infection rates are fairly steady in the United States, but skyrocketing elsewhere. We can't afford to wait for a vaccine."

When taken twice a day, nevirapine is one part of routine anti-retroviral therapy to keep HIV infection from resulting in AIDS. In small, one-time-only doses, the Johns Hopkins researchers already have proven -- overseas -- that nevirapine cuts in half the risk an HIV-infected mother will pass the virus to her baby during childbirth.

The new study tested the safety of three different doses of nevirapine – all just a fraction of the treatment dose – in 33 people at high risk of contracting HIV because of sexual practices or injection drug use. No serious adverse side effects related to nevirapine were seen in any participants, and none contracted HIV during the study period, the scientists report.

"This study wasn't designed to test whether nevirapine could in fact prevent HIV transmission, but it would have been bad for the future of this effort if we'd detected significant side effects or new infection," notes Jackson. "The important thing is that the treatment doses were well tolerated, and now we feel comfortable moving forward."

While it can take as long as six months after exposure for HIV to appear, today's HIV tests (which detect antibodies created to battle the virus) can reliably catch a new infection within four to six weeks of exposure, notes Jackson.

At treatment-level doses of 200 milligrams twice a day, the risk of liver damage is serious enough when used with other anti-retroviral drugs that nevirapine is not used to prevent HIV infection after suspected exposure (such as in health care workers or rape victims). The three much-lower doses tested were chosen to spare the liver, yet keep blood levels of the drug high enough to potentially provide a benefit.

Participants were divided into three groups: the first 12 received one tablet (200 milligrams) of nevirapine once a week for 12 weeks, the second group of 12 received one tablet twice a week, and the third group of nine took one tablet every other day. The scientists tested for HIV and hepatitis B and C infection and measured participants' liver function throughout the study period.

No clinically severe or life-threatening side effects were seen at any dose, says Jackson. However, participants susceptible to liver damage for reasons other than nevirapine (hepatitis C infection, excessive alcohol consumption, or exposure to toxic chemicals) were more likely to have slightly elevated liver enzymes (a measure of liver function) while taking the drug, regardless of dose.

Importantly, the researchers discovered that at all doses, blood levels of the drug seemed high enough to potentially prevent HIV infection. While the necessary blood level of nevirapine to prevent HIV infection in people is unknown, in the lab 10 nanograms of the drug per milliliter is enough to inhibit the virus.

"We decided on a blood level of drug 10 times that as the lowest desirable level in our study, but we don't know yet whether that will prevent infection," notes Jackson. That determination will begin with a large clinical trial, currently in the planning stages.

Tested just before getting their next dose of nevirapine, almost all participants had at least the desired level of nevirapine in their blood. While no new infections were noted, one participant with longstanding hepatitis B infection no longer tested positive after two weekly doses of nevirapine, a finding worth pursuing, says Jackson.

A few participants had blood levels of nevirapine as high as those typically seen with treatment-size doses, which could possibly contribute to liver damage over time. Another concern is that chronic use of nevirapine or another medicine might make the drug less useful if HIV infection does occur, notes Jackson. However, if the drug is well tolerated and prevents infection, that may be a risk worth taking, he adds.

The study was funded by the Johns Hopkins School of Medicine Department of Pathology. Authors on the report are Jackson, Scott Barnett, Estelle Piwowar-Manning, Linda Apuzzo, Charles Raines, Craig Hendrix, Fayez Hamzeh and Joel Gallant, all of Johns Hopkins.



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® FibroSleep™ Vitamin D3 Extreme™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Natural Pain Relief Supplements

Featured Products

Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

The New Dual Activation Pain Relief Cream The New Dual Activation Pain Relief Cream
Green Coffee Extract: Unique Obesity Intervention Green Coffee Extract: Unique Obesity Intervention
Herbal Inflammation Management for Whole Body Health Herbal Inflammation Management for Whole Body Health
The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol The Most Powerful Natural Antioxidant Discovered to Date - Hydroxytyrosol
Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant Improvements in Memory, Learning, and Cognition.3 Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant Improvements in Memory, Learning, and Cognition.3

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map